Drugs / YOLT-203
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06892301 | Feb 2025 → Jul 2026 overdue | primary hyperoxaluria type 1 | Guangzhou Women and Children's Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06511349 | Jul 2024 → Dec 2026 expected | primary hyperoxaluria type 1 | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07587021 | Jun 2026 → Aug 2027 expected | primary hyperoxaluria type 1 | YolTech Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YOLT-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07587021 ↗ |
| Route | Intravenous | “The IP is administered intravenously at the predetermined dose.” NCT06511349 ↗ |